Deciphera Pharmaceuticals Inc DCPH Stock Analysis
- Nasdaq
- Stock
- Market closed · opens Monday 9:30 AM ET
$25.59 unchanged at close Nov 6
Last close · Previous close $25.59
- Market cap
- $2.07BAt the Nov 6 close
- P/E ratio
- n/mLoss over last 12 months
- Diluted EPS
- −$2.21Last 12 months
- Dividend yield
- NoneLast 12 months
Price chart
$25.59unchangedPast month
Use the left and right arrow keys to move along the chart.
Price data
Trading
- Previous close$25.59Nov 5
- Volume0.00Nov 6 session
Shares traded on all US exchanges in the last completed session. Live intraday volume covers IEX only, so it is left out.
- Avg. volume0.00Last 21 sessions
The average daily shares traded over the last 21 trading sessions, about one calendar month.
- 52-week range: $25.59 to $25.59; now $25.59
The lowest and highest trades over the past 52 weeks, adjusted for splits. The marker shows the latest price.
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
Performance
Past performance, measured to the Nov 6 close. Total return includes reinvested dividends.Price change only, without dividends. Compared with the S&P 500, using SPY.
DCPH beat the S&P 500 in all 4 periods.
| Period | DCPH and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | DCPH: unchanged S&P 500: down 5.6% | DCPH beat the S&P 500 by 5.6 percentage points Beat |
| 3M | DCPH: unchanged S&P 500: down 4.1% | DCPH beat the S&P 500 by 4.1 percentage points Beat |
| Long term | ||
| 3Y | DCPH: up 112.2% S&P 500: up 75.0% +28.5% vs +20.5% a year | DCPH beat the S&P 500 by 37.2 percentage points Beat |
| 5Y | DCPH: up 190.1% S&P 500: up 67.8% +23.7% vs +10.9% a year | DCPH beat the S&P 500 by 122.3 percentage points Beat |
$10,000 invested in DCPH 5 years ago (Nov 5, 2021) would be worth about $29,014 at the close on , with dividends reinvested. The same amount in the S&P 500 would be worth about $16,782.
DCPH beat the S&P 500 in all 4 periods.
| Period | DCPH and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | DCPH: unchanged S&P 500: down 5.6% | DCPH beat the S&P 500 by 5.6 percentage points Beat |
| 3M | DCPH: unchanged S&P 500: down 4.3% | DCPH beat the S&P 500 by 4.3 percentage points Beat |
| Long term | ||
| 3Y | DCPH: up 112.2% S&P 500: up 68.8% +28.5% vs +19.1% a year | DCPH beat the S&P 500 by 43.4 percentage points Beat |
| 5Y | DCPH: up 190.1% S&P 500: up 56.9% +23.7% vs +9.4% a year | DCPH beat the S&P 500 by 133.2 percentage points Beat |
$10,000 invested in DCPH 5 years ago (Nov 5, 2021) would be worth about $29,014 at the close on , not counting dividends. The same amount in the S&P 500 would be worth about $15,694.
All-time high
$69.93
Closing high on . Now 63.4% below that record.
Split-adjusted daily closes since Sep 28, 2017.
Stock splits
DCPH hasn’t split since its price history begins in 2017.
Valuation
The Nov 6 close compared with the last 12 months of reported results (the four quarters to Mar 31, 2024). Tap a metric to see how it’s calculated.
Price-to-earnings (P/E)
n/mDiluted EPS of −$2.21 over the last 12 months
A P/E ratio isn’t meaningful while earnings over the last 12 months are negative. How to read P/E
Other valuation measures
- 11.8×Last 12 months’ revenue
Market value divided by revenue over the last 12 months. Useful when earnings are small or negative.
P/S = Market cap ÷ Revenue (last 12 months)Price-to-sales ratio - 6.5×Book value as of Mar 31, 2024
Price relative to accounting equity (book value) per share on the Mar 31, 2024 balance sheet. Asset-light companies often trade far above book value.
P/B = Price ÷ Book value per sharePrice-to-book ratio - −7.37%Last 12 months’ free cash flow
Free cash flow over the last 12 months as a share of the company’s market value: the cash the business generated for each dollar of stock.
FCF yield = Free cash flow (last 12 months) ÷ Market capFree cash flow - $1.82BAt the Nov 6 close
What it would cost to buy the whole business: the market cap at the Nov 6 close, plus debt, minus cash and short-term investments from the Mar 31, 2024 balance sheet.
EV = Market cap + Debt − Cash and short-term investmentsEV/EBITDA explained
Build your own DCPH DCF in Excel. Value Deciphera Pharmaceuticals with your own growth and margin assumptions.Browse DCF models Free DCF calculator
Financials
Reported results, not forecasts. From company filings via Tiingo; the latest report is Q1 FY24, the quarter ended Mar 31, 2024. “Last 12 months” means the four quarters from Apr 1, 2023 to Mar 31, 2024, and balance-sheet figures are as of Mar 31, 2024.
Revenue and net income
Last 12 months, with the change from the 12 months before
- Revenue
- $174.91Mup 26.5%
- Net income
- −$190.42M
- Diluted EPS
- −$2.21
Data table
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| Q2 FY22 (Jun 30, 2022) | $32.49M | −$43.06M | −$0.60 |
| Q3 FY22 (Sep 30, 2022) | $35.97M | −$43.04M | −$0.55 |
| Q4 FY22 (Dec 31, 2022) | $36.35M | −$45.94M | −$0.55 |
| Q1 FY23 (Mar 31, 2023) | $33.45M | −$49.61M | −$0.60 |
| Q2 FY23 (Jun 30, 2023) | $38.30M | −$48.56M | −$0.57 |
| Q3 FY23 (Sep 30, 2023) | $43.31M | −$49.58M | −$0.58 |
| Q4 FY23 (Dec 31, 2023) | $48.29M | −$47.19M | −$0.54 |
| Q1 FY24 (Mar 31, 2024) | $45.00M | −$45.08M | −$0.52 |
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| FY20 (Dec 31, 2020) | $42.09M | −$266.49M | −$4.78 |
| FY21 (Dec 31, 2021) | $96.15M | −$299.96M | −$5.16 |
| FY22 (Dec 31, 2022) | $134.04M | −$178.93M | −$2.37 |
| FY23 (Dec 31, 2023) | $163.36M | −$194.94M | −$2.29 |
Margins
- Gross 97.0%
- Operating −118.1%
- Net −108.9%
The percentages above the chart cover the last 12 months; the lines show each quarter. What margins tell you
Cash flow
- −$152.39MLast 12 months
Cash from operations minus capital spending: the cash left after the business maintains and grows its assets.
FCF = Operating cash flow − Capital spendingFree cash flow - Operating cash flow−$151.83MLast 12 months
- Capital spending$564.00KLast 12 months
- −87.1%Last 12 months
Free cash flow as a share of revenue, both over the last 12 months.
Shareholder returns
- $17.20MLast 12 months
Cash spent repurchasing shares, net of shares issued. Buybacks shrink the share count, so each remaining share owns more of the company.
- Dividends paid$0.00Last 12 months
- Total returned$0.00Last 12 months
Balance sheet
- $307.44MAs of Mar 31, 2024
Cash plus short- and long-term marketable securities on the Mar 31, 2024 balance sheet.
- Total debt$25.02MAs of Mar 31, 2024
- Net cash$282.42MAs of Mar 31, 2024
- 4.19As of Mar 31, 2024
Current assets divided by current liabilities on the Mar 31, 2024 balance sheet. Above 1 means short-term assets cover the bills due within a year.
Current ratio = Current assets ÷ Current liabilitiesCurrent ratio - 0.08As of Mar 31, 2024
Total debt divided by shareholders’ equity on the Mar 31, 2024 balance sheet: a measure of financial leverage.
D/E = Total debt ÷ Shareholders’ equityDebt-to-equity ratio
Financial strength
- 4 of 9Last 12 months
vs the 12 beforeA 0–9 checklist from accounting professor Joseph Piotroski. Each test compares the last 12 months with the 12 months before and scores a point if it passes. 8–9 is strong; 0–2 is weak.
- ✗Net income was positive: not passed
- ✗Operating cash flow was positive: not passed
- ✓Return on assets improved: passed
- ✓Operating cash flow exceeded net income: passed
- ✓Long-term debt fell relative to assets: passed
- ✗Current ratio improved: not passed
- ✗Share count didn’t rise: not passed
- ✓Gross margin improved: passed
- ✗Asset turnover (revenue ÷ assets) improved: not passed
- −52.4%Last 12 months
Over the last 12 months, Deciphera Pharmaceuticals lost money: its net loss was 52.4% of its shareholders’ equity (averaged over the last four quarter-ends). It describes the past year, not an expected return.
ROE = Net income (last 12 months) ÷ Average equityReturn on equity - −40.0%Last 12 months
Over the last 12 months, Deciphera Pharmaceuticals’s net loss was 40.0% of its total assets (averaged over the last four quarter-ends).
ROA = Net income (last 12 months) ÷ Average total assets
About Deciphera Pharmaceuticals Inc
Deciphera Pharmaceuticals Inc
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Headquarters
- Massachusetts, USA
- SEC filings
- EDGAR (opens in a new tab)
- Exchange
- Nasdaq
- Asset type
- Common stock
- Price history since
DCPH news
Explore more stocks
Prices are from the last refresh. Open any stock for its live dashboard.
Popular stocks
DCPH stock FAQ
What is DCPH stock’s price today?
Deciphera Pharmaceuticals (DCPH) traded at $25.59 at the close on , unchanged from the previous close of $25.59. Over the past 52 weeks it has traded between $25.59 and $25.59.
If you invested $1,000 in DCPH 5 years ago, how much would you have now?
With dividends reinvested, $1,000 invested in DCPH on would be worth about $2,901 at the close on , a total return of +190.1%. Past performance doesn’t predict future returns.
What is Deciphera Pharmaceuticals’s market cap?
Deciphera Pharmaceuticals’s market capitalization is about $2.1 billion. That’s Tiingo’s daily market cap for , at that day’s closing price of $25.59 (how market cap works). Deciphera Pharmaceuticals reported 80.80M shares outstanding at the end of its latest quarter ().
What is DCPH’s P/E ratio?
DCPH’s P/E ratio isn’t meaningful right now because its earnings over the four quarters to are negative (diluted EPS of −$2.21).
How much revenue does Deciphera Pharmaceuticals make?
Deciphera Pharmaceuticals reported $174.9 million of revenue over the four quarters to , up 26.5% from the twelve months before. In its latest quarter (Q1 FY24, ended ) revenue was $45.0 million, up 34.5% from a year earlier.
Is Deciphera Pharmaceuticals profitable?
Not over the four quarters to . Deciphera Pharmaceuticals reported a net loss of $190.4 million across those four quarters on $174.9 million of revenue.
What are DCPH’s earnings per share?
DCPH’s diluted earnings per share were −$2.21 over the four quarters to , compared with −$2.30 in the twelve months before. The latest quarter (Q1 FY24) brought −$0.52 per share, against −$0.60 a year earlier (how EPS works).
Does DCPH pay a dividend?
Deciphera Pharmaceuticals hasn’t paid a dividend in the last twelve months.
What is DCPH’s 52-week high and low?
Over the past 52 weeks DCPH has traded as low as $25.59 and as high as $25.59. At $25.59 at the close on , it is 0.0% below that high and 0.0% above the low.
What is DCPH’s all-time high?
DCPH’s highest closing price was $69.93 on , adjusted for stock splits. At $25.59 at the close on , it is 63.4% below that record.
Has DCPH stock ever split?
No. DCPH hasn’t split since its price history begins in 2017.
What sector and industry is Deciphera Pharmaceuticals in?
Deciphera Pharmaceuticals is in the Healthcare sector and the Drug Manufacturers - Specialty & Generic industry, and is headquartered in Massachusetts, USA.
What exchange does DCPH trade on?
Deciphera Pharmaceuticals trades on the Nasdaq under the ticker symbol DCPH. Its price history on this dashboard begins on .
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
About this data. Data sourced by Tiingo (opens in a new tab). The live price is Tiingo’s real-time price, based on IEX trades and quotes; intraday charts show IEX trades, and volume figures are consolidated totals for completed sessions. Prices are split-adjusted, and total returns assume dividends are reinvested. Financials come from company filings and can lag new reports. Times are Eastern.
This page is for education, not investment advice. Past performance doesn't predict future returns. Logos provided by Logo.dev (opens in a new tab).
The Interactive Brokers word and logo are trademarks of Interactive Brokers LLC (or its subsidiaries) in the US and/or elsewhere. All rights reserved.